JLS Fund
www.jls.fundVCMatch tracks JLS Fund as an investor focused on Biotech, Pharma, and Digital Health companies and Series C rounds. Upload your deck to compare your startup against the full private matching profile.
Check Size
Not specified
Stages
Focus Areas
Geography
Not specified
Investment Thesis
JLS Fund positions itself as a specialist early-stage VC that “creates tools and infrastructure for the precision neuroscience era.” The firm explicitly focuses on financing and operationally supporting companies that “translate breakthroughs in neuroscience, technology, and data into outcomes for patients—and value for strategic acquirers,” emphasizing translational impact (patient outcomes) alongside commercial exit-readiness (strategic acquirers).
Is JLS Fund right for your startup?
Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.
Investment Focus
Who should take a closer look
JLS Fund is most relevant for founders raising Series C rounds in Biotech, Pharma, Digital Health, and Medtech.
Focus statement
JLS Fund's stated focus is "creating tools and infrastructure for the precision neuroscience era" and financing companies that "translate breakthroughs in neuroscience, technology, and data into outcomes for patients—and value for strategic acquirers."
Value Add
- Explicit infrastructure and tools focus (not only drugs): the site states the fund is "creating tools and infrastructure for the precision neuroscience era," signaling emphasis on platforms, devices, data and enabling technologies rather than only novel therapeutics.
- Translational + acquirer-aware thesis: they pair patient-outcome goals with building "value for strategic acquirers," indicating an approach tuned to both clinical impact and M&A/value realization.
- Deep domain engagement and thought leadership: extensive event/panel participation and content on psychedelics, MDMA, psilocybin, neurotechnology and policy (many panels and speaking engagements listed) shows active ecosystem development and sector expertise.
- Advisors and team with psychedelic/neuroscience pedigree: the site highlights advisors and contributors (e.g., Leonard Pickard, Gul Dolen, Walter Greenleaf) and managing partners active across the space, which is a distinctive network asset for founders.
- Cross‑sector orientation: coverage of neuroscience, psychedelics, wearable haptics, and regulatory/policy trends suggests a multidisciplinary investment lens (neuroscience + tech + data + policy).
Stage And Sector Fit
Portfolio Highlights
Aspen Neuroscience
Biotech
Clearmind
Psychedelic Biotech
VoxeLite
Neurotech Haptics
OrbiMed
Venture Capital
ARCH Venture Partners
Venture Capital
Gilead
Pharma
ATAI
Psychedelic Biotech
Numinus
Psychedelic Services
+ 18 more companies in their portfolio
Ready to find your perfect investor match?
Get Started Free